Green Leaf Pharmaceuticals Posts 24.8% Rise In Interim Profit

Green Leaf Pharmaceuticals (02186) reported interim profit of RMB 390 million for the six months ended June 30, up 24.8% year on year, and said it will not pay an interim dividend, according to ETNet. Earnings per share were 9.78 fen. Revenue fell 5.6% to RMB 3 billion, mainly because sales of product technologies declined. Gross profit dropped 11.8% to RMB 1.9 billion, while the gross margin narrowed 4.4 percentage points to 63.4% due mainly to higher cost of sales. EBITDA rose 3.9% to RMB 1.25 billion. The group said it has launched more than 50 products across oncology, central nervous system, cardiovascular and other therapeutic areas.